Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 3/2009

01-07-2009 | Special Feature

Gene and chromosomal alterations in sporadic breast cancer: correlation with histopathological features and implications for genesis and progression

Author: Hitoshi Tsuda

Published in: Breast Cancer | Issue 3/2009

Login to get access

Abstract

A number of gene and chromosome alterations have been identified in sporadic breast carcinomas, and their clinical implications have been investigated. Changes in proto-oncogenes and tumor-suppressor genes, e.g., HER2, p53, and E-cadherin, and various numerical and structural chromosome alterations are strongly correlated with histological type and grade in breast carcinomas. The amount of information on these alterations has been dramatically increased by the introduction of high-throughput molecular cytogenetic approaches. In the near future, breast cancers will be classified into specific groups according to their profile of gene and chromosome alterations, allowing more effective personalized therapies targeting the associated molecular pathways.
Literature
1.
2.
Fukutomi T, Ushijima T, Inoue R, Akashi-Tanaka S, Nanasawa T, Tsuda H. BRCA1 and BRCA2 germline mutations in Japanese with hereditary breast cancer families. Breast Cancer. 1997;4:256–8.PubMedCrossRef
3.
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66–71.PubMedCrossRef
4.
Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet. 1996;12:333–7.PubMedCrossRef
5.
Katagiri T, Kasumi F, Yoshimoto M, Nomizu T, Asaishi K, Abe R, et al. High proportion of missense mutations of the BRCA1 and BRCA2 genes in Japanese breast cancer families. J Hum Genet. 1998;43:42–8.PubMedCrossRef
6.
Lakhani SR, Easton DF, Stratton MR. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet. 1997;349:1505–10.CrossRef
7.
Noguchi S, Kasugai T, Miki Y, Fukutomi T, Emi M, Nomizu T. Clinicopathologic analysis of BRCA1- or BRCA2-associated hereditary breast carcinoma in Japanese women. Cancer. 1999;85:2200–5.PubMedCrossRef
8.
Brugarolas J, Jacks T. Double indemnity: p53, BRCA and cancer. p53 mutation partially rescues developmental arrest in Brca1 and Brca2 null mice, suggesting a role for familial breast cancer genes in DNA damage repair. Nat Med. 1997;3:721–2.PubMedCrossRef
9.
10.
11.
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portlaits of human breast tumors. Nature. 2000;406:747–52.PubMedCrossRef
12.
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–74.PubMedCrossRef
13.
Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100:8418–23.PubMedCrossRef
14.
Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 2008;14:5158–65.PubMedCrossRef
15.
Fadare O, Tavassoli FA. Clinical and pathologic aspects of basal-like breast cancers. Nat Clin Pract Oncol. 2008;5:149–59.PubMedCrossRef
16.
Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol. 2008;26:2568–81.PubMedCrossRef
17.
Goldhirsch A, Wood W, Gelber R, Coates A, Thurlimann B, Senn HJ. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007;18:1133–44.PubMedCrossRef
18.
19.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–82.PubMedCrossRef
20.
van de Vijver M, van de Bersselaar R, Devilee P, Cornelisse C, Peterse J, Nusse R. Amplification of the neu (c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol Cell Biol. 1987;7:3019–23.
21.
Berger MS, Locher GW, Sauer S, Gulluck WJ, Waterfield MD, Groner B, et al. Correlation of c-erbB-2 gene amplification and protein overexpression in human breast cancer with nodal status and nuclear grading. Cancer Res. 1988;48:1238–43.PubMed
22.
Tsuda H, Hirohashi S, Shimosato Y, Hirota T, Tsugane S, Yamamoto H, et al. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. Cancer Res. 1989;49:3104–8.PubMed
23.
Kallioniemi O-P, Kallioniemi A, Kurisu W, Thor A, Chen LC, Smith HS, et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci USA. 1992;89:5321–5.PubMedCrossRef
24.
Mitchell MS, Press MF. The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognosis of breast cancer. Semin Oncol. 1999;26:108–16.PubMed
25.
Tsuda H, Hirohashi S, Shimosato Y, Hirota T, Tsugane S, Watanabe S, et al. Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma: a retrospective analysis of 176 cases. Cancer. 1990;65:1794–800.PubMedCrossRef
26.
Iwaya K, Tsuda H, Hiraide H, Tamaki K, Tamakuma S, Fukutomi T, et al. Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Jpn J Cancer Res. 1991;82:835–40.PubMed
27.
Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253:49–53.PubMedCrossRef
28.
Osborne RJ, Merlo GR, Mitsudomi T, Venesio T, Liscia DS, Cappa AP, et al. Mutations in the p53 gene in primary human breast cancers. Cancer Res. 1991;51:6194–8.PubMed
29.
Tsuda H, Iwaya K, Fukutomi T, Hirohashi S. p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade. Jpn J Cancer Res. 1993;84:394–401.PubMed
30.
Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med. 1995;1:1029–34.PubMedCrossRef
31.
Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J, et al. The clinical value of somatic TP53 gene mutations in 1, 794 patients with breast cancer. Clin Cancer Res. 2006;12:1157–67.PubMedCrossRef
32.
Ozcelik H, Pinnaduwage D, Bull SB, Andrulis IL. Type of TP53 mutation and ERBB2 amplification affects survival in node-negative breast cancer. Breast Cancer Res Treat. 2007;105:255–65.PubMedCrossRef
33.
Escot C, Theillet C, Lidereau R, Spyratos F, Champeme ME, Gest J, et al. Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. Proc Natl Acad Sci USA. 1986;83:4834–8.PubMedCrossRef
34.
Ali IU, Lidereau R, Theillet C, Callahan R. Reduction to homozygosity of genes on chromosome 11 in human breast neoplasia. Science. 1987;238:185–8.PubMedCrossRef
35.
Chen L-C, Neubauer A, Kurisu W, Waldman FM, Ljung B-M, Goodson WIII, et al. Loss of heterozygosity on the short arm of chromosome 17 is associated with high proliferative capacity and DNA aneuploidy in primary human breast cancer. Proc Natl Acad Sci USA. 1991;88:3847–51.PubMedCrossRef
36.
Devilee P, van Vliet M, Bardoel A, KIevits T, Kuipers-Dijkshoorn N, Pearson PL, et al. Frequent somatic imbalance of marker alleles for chromosome 1 in human primary breast carcinoma. Cancer Res. 1991;51:1020–5.PubMed
37.
Bieche I, Champeme MH, Matifas F, Hacene K, Callahan R, Lidereau R. Loss of heterozygosity on chromosome 7q and aggressive primary breast cancer. Lancet. 1992;339:139–43.PubMedCrossRef
38.
Sato T, Tanigami A, Yamakawa K, Akiyama F, Kasumi F, Sakamoto G, et al. Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer. Cancer Res. 1990;50:7184–9.PubMed
39.
Tsuda H, Callen DF, Fukutomi T, Nakamura Y, Hirohashi S. Allele loss on chromosome 16q24.2-qter occurs frequently in breast cancers irrespectively of differences in phenotype and extent of spread. Cancer Res. 1994;54:513–7.PubMed
40.
Cleton-Jansen A-M, Moerland EW, Kuipers-Dijkshoorn N, Cullen DF, Sutherland GR, Hansen B, et al. At least two different regions are involved in allelic imbalance on chromosome arm 16q in breast cancer. Genes Chromosomes Cancer. 1994;9:101–7.PubMedCrossRef
41.
Matsumura K, Kallioniemi A, Kallioniemi O, Chen L, Smith HC, Pinkel D, et al. Deletion of chromosome 17p loci in breast cancer cells detected by fluorescence in situ hybridization. Cancer Res. 1992;52:3474–7.PubMed
42.
Ichikawa D, Hashimoto N, Hoshima M, Yamaguchi T, Sawai K, Nakamura Y, et al. Analysis of numerical alterations in specific chromosomes by fluorescence in situ hybridization (FISH) as a diagnostic tool in breast cancer. Cancer. 1996;77:2064–9.PubMedCrossRef
43.
Dutrillaux B, Gerbault-Seureau M, Remvikos Y, Zafrani B, Prieur M. Breast cancer genetic evolution. I. Data from cytogenetics and DNA content. Breast Cancer Res Treat. 1991;19:245–55.PubMedCrossRef
44.
Kokalj-Vokac N, Alemeida A, Gerbault-Seureau M, Malfoy B, Dutrillaux B. Two-color FISH characterization of i(1q), and der(1;16) in human breast cancer cells. Genes Chromosomes Cancer. 1993;7:8–14.PubMedCrossRef
45.
Tsuarouha H, Pandis N, Bardi G, Teixeira MR, Andersen JA, Heim S. Karyotypic evolution in breast carcinomas with i(1)(q10) and der(1;16)(q10;p10) as the primary chromosome abnormality. Cytogenet Cell Genet. 1999;113:156–61.CrossRef
46.
Kanai Y, Oda T, Tsuda H, Ochiai A, Hirohashi S. Point mutation of the E-cadherin gene in invasive lobular carcinoma of the breast. Jpn J Cancer Res. 1994;85:1035–9.PubMed
47.
Berx G, Cleton-Jansen A-M, Nollet F, de Leeuw WJF, van de Vijver MJ, Cornelisse C, et al. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J. 1995;14:6107–15.PubMed
48.
Berx G, Cleton-Jansen A-M, Strumane K, de Leeuw WJF, Nollet F, van Roy F, et al. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene. 1996;13:1919–25.PubMed
49.
Droufakou S, Deshmane V, Roylance R, Hanby A, Tomlinson I, Hart IR. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int J Cancer. 2001;92:404–8.PubMedCrossRef
50.
Sarrio D, Moreno-Bueno G, Hardisson D, Sanchez-Estevez C, Guo M, Herman JG, et al. Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. Int J Cancer. 2003;106:208–15.PubMedCrossRef
51.
Catteau A, Harris WH, Xu CF, Solomon E. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene. 1999;18:1957–65.PubMedCrossRef
52.
Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000;92:564–9.PubMedCrossRef
53.
Miyamoto K, Fukutomi T, Asada K, Wakazono K, Tsuda H, Asahara T, et al. Promoter hypermethylation and post-transcriptional mechanisms responsible for reduced BRCA1 immunoreactivity in sporadic human breast cancers. Jpn J Clin Oncol. 2002;32:79–84.PubMedCrossRef
54.
Staff S, Isola J, Tanner M. Haplo-insufficiency of BRCA1 in sporadic breast cancer. Cancer Res. 2003;63:4978–83.PubMed
55.
Wei M, Grushko TA, Dignam J, Hagos F, Nanda R, Sveen L, et al. BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res. 2005;65:10692–9.PubMedCrossRef
56.
Fukushige S, Matsubara K, Yoshida M, Sasaki M, Suzuki T, Semba K, et al. Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification is a gastric cancer cell line. Mol Cell Biol. 1986;6:955–8.PubMed
57.
Kallioniemi A, Kallioniemi OP, Piper J, Tanner M, Stokke T, Chen L, et al. Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc Natl Acad Sci USA. 1994;91:2156–60.PubMedCrossRef
58.
Inazawa J, Ichikawa D, Date Y. New technology in cytolopathology. Analysis of chromosomal abnormalities by fluorescence in situ hybridization (FISH) and cancer cytopathology for cytopathological specimens of breast cancer. Byouri to Rinsho. 1996;14:1240–6. (in Japanese).
59.
Courjal F, Theillet C. Comparative genomic hybridization analysis of breast tumors with predetermined profiles of DNA amplification. Cancer Res. 1997;57:4368–77.PubMed
60.
Tsuda H, Takarabe T, Susumu N, Inazawa J, Okada S, Hirohashi S. Detection of numerical and structural alterations and fusion of chromosomes 16 and 1 in low-grade papillary breast carcinoma by fluorescence in situ hybridization. Am J Pathol. 1997;151:1027–34.PubMed
61.
Tirkkonen M, Tanner M, Karhu R, Kallioniemi A, Isola J, Kallioniemi OP. Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer. 1998;21:177–84.PubMedCrossRef
62.
Tsuda H, Takarabe T, Hirohashi S. Correlation of the numerical and structural status of chromosome 16 with the histological type and grade of non-invasive and invasive breast carcinomas. Int J Cancer. 1999;84:381–7.PubMedCrossRef
63.
Nailor TL, Greshock J, Wang Y, Colligon T, Clemmer V, Zaks TZ, et al. High resolution genomic analysis of sporadic breast cancer using array-based comparative genomic hybridization. Breast Cancer Res. 2005;7:R1186–98.CrossRef
64.
Roylance R, Gorman P, Papior T, Wan YL, Ives M, Watson JE, et al. A comprehensive study of chromosome 16q in invasive ductal and lobular breast carcinoma using array CGH. Oncogene. 2006;25:6544–53.PubMedCrossRef
65.
Climent J, Garcia JL, Mao JH, Arsuaga J, Perez-Losada J. Characterization of breast cancer by array comparative genomic hybridization. Biochem Cell Biol. 2007;85:497–508.PubMedCrossRef
66.
Tsuda H, Takarabe T, Fukutomi T, Hirohashi S. der(16)t(1;16)/der(1;16) in breast cancer detected by fluorescence in situ hybridization is an indicator of better patient prognosis. Genes Chromosomes Cancer. 1999;24:72–7.PubMedCrossRef
67.
Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, et al. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature. 1986;319:230–4.PubMedCrossRef
68.
Jin Q, Esteva FJ. Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J Mammary Gland Biol Neoplasia. 2008;13:485–98.PubMedCrossRef
69.
Tsuda H. HER-2 (c-erbB-2) test update: present status and problems. Breast Cancer. 2006;13:236–48.PubMedCrossRef
70.
Paik S, Bryant J, Tan-Chiu E, Yothers G, Park C, Wickerham DL, et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: national surgical adjuvant breast and bowel project protocol B-15. J Natl Cancer Inst. 2000;92:1991–8.PubMedCrossRef
71.
Toi M, Nakamura S, Kuroi K, Iwata H, Ohno S, Masuda N, et al. Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. Breast Cancer Res Treat. 2008;110:531–9.PubMedCrossRef
72.
van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med. 1988;319:1239–45.PubMed
73.
Tsuda H, Fukutomi T, Hirohashi S. Pattern of gene alterations in intraductal breast neoplasms associated with histological type and grade. Clin Cancer Res. 1995;1:261–7.PubMed
74.
Tsuda H, Hirohashi S. Multiple developmental pathways to highly aggressive breast cancers disclosed by comparison of histologic grades and c-erbB-2 expression patterns in both the intraductal and invasive portions. Pathol Int. 1998;48:518–25.PubMedCrossRef
75.
Knudson AG Jr, Hethcote HW, Brown BW. Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma. Proc Natl Acad Sci USA. 1975;72:5116–20.PubMedCrossRef
76.
Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature. 1990;348:747–9.PubMedCrossRef
77.
Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990;250:1233–8. erratum in science. 1993;259:878.PubMedCrossRef
78.
Donehower LA, Bradley A. The tumor suppressor p53. Biochim Biophys Acta. 1993;1155:181–205.PubMed
79.
80.
Oren M, Gottlieb TM, Oren M. p53 in growth control and neoplasia. Biochim Biophys Acta. 1996;1287:77–102.PubMed
81.
Toledo F, Wahl GM. Regulating the p53 pathway: in vitro and in vivo veritas. Nat Rev Cancer. 2006;6:909–23.PubMedCrossRef
82.
Tsuda H, Hirohashi S. Association among p53 gene mutation, nuclear accumulation of the p53 protein and aggressive phenotypes in breast cancer. Int J Cancer. 1994;57:498–503.PubMedCrossRef
83.
Vincent-Salomon A, Gruel N, Lucchesi C, MacGrogan G, Dendale R, Sigal-Zafrani B, et al. Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res. 2007;9:R24.PubMedCrossRef
84.
Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol. 1998;153:333–9.PubMed
85.
Stange DE, Radlwimmer B, Schubert F, Traub F, Pich A, Toedt G, et al. High-resolution genomic profiling reveals association of chromosomal aberrations on 1q and 16p with histologic and genetic subgroups of invasive breast cancer. Clin Cancer Res. 2006;12:345–52.PubMedCrossRef
86.
Cleton-Jansen AM, Buerger H, Haar N, Philippo K, van de Vijver MJ, Boecker W, et al. Different mechanisms of chromosome 16 loss of heterozygosity in well- versus poorly differentiated ductal breast cancer. Genes Chromosomes Cancer. 2004;41:109–16.PubMedCrossRef
87.
Tsuda H, Uei Y, Fukutomi T, Hirohashi S. Different incidence of loss of heterozygosity on chromosome 16q between intraductal papilloma and intracystic papillary carcinoma of the breast. Jpn J Cancer Res. 1994;85:992–6.PubMed
88.
Lakhani SR, Collins N, Stratton MR, Sloane JP. Atypical ductal hyperplasia of the breast: clonal proliferation with loss of heterozygosity on chromosomes 16q and 17p. J Clin Pathol. 1995;48:611–5.PubMedCrossRef
89.
Tsuda H, Takarabe T, Akashi-Tanaka S, Fukutomi T, Hirohashi S. Pattern of loss of heterozygosity on chromosome 16q differs between an atypical proliferative lesion and a ductal carcinoma which occurred metachronously at the same area of the breast. Mod Pathol. 2001;14:382–8.PubMedCrossRef
90.
Tsuda H, Takarabe T, Fukutomi T, Hirohashi S. Preferential occurrence of breast carcinomas with loss of 16q and der(16)t(1;16)/der(1;16) in middle-aged patients with hyperproliferative changes in mammary glands. Jpn J Cancer Res. 2000;91:692–9.PubMed
91.
Tsuda H, Sakamaki C, Tsugane S, Fukutomi T, Hirohashi S. A prospective study on the significance of gene and chromosome alterations as prognostic indicators of breast cancer patients with lymph node metastases. Breast Cancer Res Treat. 1998;48:21–32.PubMedCrossRef
92.
Emi M, Yoshimoto M, Sato T, Matsumoto S, Utada Y, Ito I. et al. Allelic loss at 1p34, 13q12, 17p13.3, and 17q21.1 correlates with poor postoperative prognosis in breast cancer. Genes Chromosomes Cancer. 1999;26:134–41.PubMedCrossRef
93.
Utada Y, Emi M, Yoshimoto M, Kasumi F, Akiyama F, Sakamoto G, et al. Allelic loss at 1p34–36 predicts poor prognosis in node-negative breast cancer. Clin Cancer Res. 2000;6:3193–8.PubMed
94.
Melchor L, Benitez J. An integrative hypothesis about the origin oand development of sporadic and familial breast cancer subtypes. Carcinogenesis. 2008;29:1475–82.PubMedCrossRef
95.
Adelaide J, Finetti P, Rekhoushe I, Repellini L, Geneix J, Sircoulomb F, et al. Integrated profiling of basal and luminal breast cancers. Cancer Res. 2007;67:11565–75.PubMedCrossRef
96.
The Japanese Breast Cancer Society. General rules for clinical and pathological recording of breast cancer, the 16th edn. Kanehara Shuppan: Tokyo; 2008 (in Japanese).
97.
World Health Organization. Tumours of the breast. In: Tavassoli FA, Devilee P, editors. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press; 2003. p. 9–112.
98.
Rosen PP. The pathology of invasive breast carcinoma. In: Harris JR, Hellman S, Henderson IC, Kinne DW, editors. Breast diseases. 2nd edn. Philadelphia: J. B. Lippincott; 1991. p. 245–96.
99.
Akashi-Tanaka S, Fukutomi T, Nanasawa T, Matsuo K, Hasegawa T, Tsuda H. Treatment of noninvasive carcinoma: fifteen-year results at the National Cancer Center Hospital in Tokyo. Breast Cancer. 2000;7:341–4.PubMedCrossRef
100.
Rosen PP. Intraductal carcinoma. In: Rosen PP, editor. Rosen’s breast pathology. 2nd edn. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 253–323.
101.
Buerger H, Otterbach F, Simon R, Poremba C, Diallo R, Decker T, et al. Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways. J Pathol. 1999;187:396–402.PubMedCrossRef
102.
Vincent-Salomon A, Lucchesi C, Gruel N, Raynal V, Pierron G, et al. Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. Clin Cancer Res. 2008;14:1956–65.PubMedCrossRef
103.
Lakhani SR, Collins N, Sloane JP, Stratton MR. Loss of heterozygosity in lobular carcinoma in situ of the breast. J Clin Pathol Mol Pathol. 1995;48:M74–8.CrossRef
104.
Mohsin SK, O’Connell PO, Alled DC, Libby AL. Biomarker profile and genetic abnormalities in lobular carcinoma in situ. Breast Cancer Res Treat. 2005;90:249–56.PubMedCrossRef
105.
Volante M, Sapino A, Croce S, Bussolati G. Heterogeneous versus homogeneous genetic nature of multiple foci of in situ carcinoma of the breast. Hum Pathol. 2003;34:1163–9.PubMedCrossRef
106.
Page DL, Sakamoto G. Infiltrating carcinoma: major histologicaltypes. In: Page DL, Anderson TJ, editors. Diagnostic histopathology of the breast. Edinburgh: Churchill Livingstone; 1987. p. 193–205.
107.
Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer. 1957;11:359–77.PubMed
108.
Elston CW, Ellis IO. Pathologic prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403–10.PubMedCrossRef
109.
Le Doussal V, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos F, Brunet M. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer. 1989;64:1914–21.PubMedCrossRef
110.
Tsuda H. Individualization of breast cancer based on histopathological features and molecular alterations. Breast Cancer. 2008;15:121–32.PubMedCrossRef
111.
Yoshimoto M, Sakamoto G, Ohashi Y. Time dependency of the influence of prognostic factors on relapse in breast cancer. Cancer. 1993;72:2993–3001.PubMedCrossRef
112.
Nielsen TO, Hsu FD, Jense K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367–74.PubMedCrossRef
113.
Tsuda H, Morita D, Kimura M, Shinto E, Ohtsuka Y, Matsubara O, et al. Correlation of KIT and EGFR overexpression with invasive ductal carcinoma of solid-tubular subtype, nuclear grade 3, and mesenchymal or myoepithelial differentiation in breast cancer. Cancer Sci. 2005;96:48–53.PubMed
114.
Rakha EA, Putti TC, Abd El-Rehim DM, Paish C, Green AR, Powe DG, et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol. 2006;208:495–506.PubMedCrossRef
115.
Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF, et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol. 2004;203:661–71.PubMedCrossRef
116.
Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology. 2008;52:108–18.PubMedCrossRef
117.
Wetzels RH, Kuijpers HJ, Lane EB, Leigh IM, Troyanovsky SM, Holland R, et al. Basal cell-specific and hyperproliferation-related keratins in human breast cancer. Am J Pathol. 1991;138:751–63.PubMed
118.
Tsuda H, Takarabe T, Hasegawa T, Murata T, Hirohashi S. Myoepithelial features in high-grade invasive ductal carcinomas with large central acellular zones. Hum Pathol. 1999;30:1134–9.PubMedCrossRef
119.
Tsuda H, Takarabe T, Hasegawa F, Fukutomi T, Hirohashi S. Large central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am J Surg Pathol. 2000;24:197–202.PubMedCrossRef
120.
Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol. 1992;10:599–605.PubMed
121.
Anderson JM, Ariga R, Govil H, Bloom KJ, Francescatti D, Reddy VB, et al. Assessment of Her-2/Neu status by immunohistochemistry and fluorescence in situ hybridization in mammary Paget disease and underlying carcinoma. Appl Immunohistochem Mol Morphol. 2003;11:120–4.PubMed
122.
Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene. 2006;25:5846–53.PubMedCrossRef
123.
Jacquemier J, Padovani L, Rabayrol L, Lakhani SR, Penault-Llorca F, Denoux Y, et al. Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J Pathol. 2005;207:260–8.PubMedCrossRef
124.
Azoulay S, Laé M, Fréneaux P, Merle S, Al Ghuzlan A, Chnecker C, et al. KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. Mod Pathol. 2005;18:1623–31.PubMed
125.
Reis-Filho JS, Milanezi F, Steele D, Savage K, Simpson PT, Nesland JM, et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology. 2006;49:10–21.PubMedCrossRef
126.
O’Malley FP, Bane A. An update on apocrine lesions of the breast. Histopathology. 2008;52:3–10.PubMed
127.
Hanby AM, Hughes TA. In situ and invasive lobular neoplasia of the breast. Histopathology. 2008;52:58–66.PubMed
128.
Tavassoli FA. Infiltrating carcinoma: common and familiar special types. In: Tavassoli FA, editor. Pathology of the breast. 2nd ed. McGraw-Hill: New York; 1999. p. 401–80.
129.
Flagiello D, Gerbault-Seureau M, Sastre-Garau X, Padoy E, Vielh P, Dutrillaux B. Highly recurrent der(1;16)(q10;p10) and other 16q arm alterations in lobular breast cancer. Genes Chromosomes Cancer. 1998;23:300–6.PubMedCrossRef
130.
Wheeler DT, Tai LH, Bratthauer GL, Waldner DL, Tavassoli FA. Tubulolobular carcinoma of the breast: an analysis of 27 cases of a tumor with a hybrid morphology and immunoprofile. Am J Surg Pathol. 2004;8:1587–93.
131.
Kuroda H, Tamaru J, Takeuchi I, Ohnisi K, Sakamoto G, Adachi A, et al. Expression of E-cadherin, alpha-catenin, and beta-catenin in tubulolobular carcinoma of the breast. Virchows Arch. 2006;448:500–5.PubMedCrossRef
132.
Esposito NN, Chivukula M, Dabbs DJ. The ductal phenotypic expression of the E-cadherin/catenin complex in tubulolobular carcinoma of the breast: an immunohistochemical and clinicopathologic study. Mod Pathol. 2007;20:130–8.PubMedCrossRef
133.
Ridolfi RL, Rosen PP, Port A, Kinne D, Miké V. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer. 1977;40:1365–85.PubMedCrossRef
134.
Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst. 1998;90:1138–45.PubMedCrossRef
135.
Miyoshi Y, Murase K, Oh K. Basal-like subtype and BRCA1 dysfunction in breast cancers. Int J Clin Oncol. 2008;13:395–400.PubMedCrossRef
136.
Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, Steele D, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene. 2007;26:2126–32.PubMedCrossRef
137.
Magdinier F, Ribieras S, Lenoir GM, Frappart L, Dante R. Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region. Oncogene. 1998;17:3169–76.PubMedCrossRef
138.
Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LF, et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol. 2008;216:141–50.PubMedCrossRef
139.
Page DL, Ellis IO, Elston CW. Histologic grading of breast cancer. Let’s do it. Am J Clin Pathol. 1995;103:123–4.PubMed
140.
Koyama H, Asaishi K, Yoshimoto M, Enomoto K, Yamamoto H, Uchida M, et al. Recurrence of node-negative breast cancer. Nyugan no Rinsho. 1989;4:69–75. (in Japanese).
141.
Watanabe T, Sano M, Takashima S, Kitaya T, Tokuda Y, Yoshimoto M, et al. Oral uracil-tegafur (UFT) compared with classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: Results from national surgical adjuvant study for breast cancer (N-SAS-BC) 01 trial. J Clin Oncol. 2009;27:1368–74.PubMedCrossRef
Metadata
Title
Gene and chromosomal alterations in sporadic breast cancer: correlation with histopathological features and implications for genesis and progression
Author
Hitoshi Tsuda
Publication date
01-07-2009
Publisher
Springer Japan
Published in
Breast Cancer / Issue 3/2009
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-009-0124-x

Other articles of this Issue 3/2009

Breast Cancer 3/2009 Go to the issue

Original Article

Preoperative MRI marking technique for the planning of breast-conserving surgery

Special Feature

Current issues and perspectives on breast cancer diagnosis

Original Article

Identification of sentinel lymph node location based on body surface landmarks in early breast cancer patients

Case Report

Biphasic metaplastic sarcomatoid carcinoma of the breast: report of a case

Special Feature

Usefulness of immunohistochemistry for differential diagnosis between benign and malignant breast lesions

Review Article

Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits